Printer Friendly

Meiji Seika Pharma to unveil two ophthalmic products in Indonesia under an agreement with Santen Pharmaceutical.

M2 PHARMA-August 7, 2019-Meiji Seika Pharma to unveil two ophthalmic products in Indonesia under an agreement with Santen Pharmaceutical

(C)2019 M2 COMMUNICATIONS

Healthcare company Meiji Seika Pharma Co Ltd revealed on Tuesday the availability of DIQUAS ophthalmic solution 3% (Diquafosol Sodium) and TAFLOTAN ophthalmic solution 0.0015% (Tafluprost) in Indonesia.

The company has launched the two products in Indonesia under an agreement with Santen Pharmaceutical Co Ltd.

Santen's IQUAS ophthalmic solution 3% (Diquafosol Sodium) is used for the treatment of dry-eye and TAFLOTAN ophthalmic solution 0.0015% (Tafluprost) Glaucoma is used for the treatment of ocular hypertension.

Based on the working business agreement with Santen, these products will be marketed in Indonesia by Meiji's affiliated subsidiary, PT Meiji Indonesian Pharmaceutical Industries,which has established a new marketing team specialized on ophthalmic treatments and Santen will support their marketing activities.

In conjunction, PT Meiji and Santen will work together to expand market share in Indonesia for ophthalmic products.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:9INDO
Date:Aug 7, 2019
Words:169
Previous Article:HCL Technologies collaborates with Oracle Health Sciences.
Next Article:Evox Therapeutics awarded key exosome patents in the US and Europe.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters